How the Covid pill Paxlovid came to be

This is the story of a pharmaceutical triumph, pieced together from interviews with Pfizer's top researchers and with outside experts. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

How Paxlovid came to be: From the germ of an idea to a vital tool against Covid By Matthew Herper Charlotte Allerton, head of medicine design at Pfizer, at the company's labs in Cambridge, Mass. (Vanessa Leroy for STAT) The story of the Covid-19 treatment Paxlovid is a reminder that the path from a biological idea to a useable medicine depends on thousands of decisions, any of which can result in the medicine not making it. Read More Sponsor content by STAT Events Boston | The journey from lab to patient’s bedside Meet us on May 3 to explore the challenges, and the unique opportunities, of the drug development process with individuals working to address a diverse set of medical challenges. Get your ticket now to unpack their experiences. More great reads from STAT this week ‘Without a word for what we know’: The unfathomable loss of a million U.S. Covid deaths By Eric Boodman The doctor who is trying to bring back surprise billing By Bob Herman Experts fear U.S. may default to annual Covid boosters without sufficient data By Helen Branswell White House’s Jen Psaki offered a binder full of Covid spending details. Taking a peek was a process By Rachel Cohrs He had an M.D. and a Ph.D. but didn’t match into a residency. It was the push he needed to jump into health tech By Tino Delamerced AI can predict missed appointments. How can hospitals use that data for better care? By Mohana Ravindranath Startups are turning to a century-old technology to fuel a resurgence in neuro drug development By Allison DeAngelis Researchers test the power of machine learning to unravel long Covid’s mysteries By Katie Palmer Would drugmakers lower their insulin prices if Congress asks nicely? By Rachel Cohrs There’s a new crop of treatments for ADHD in kids. Are they any better? By Troy Farah Saturday, April 30, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser